Skip to content
Clinical Trials – home
PolandBack to Poland

Clinical trials in Gdansk – page 8

865 clinical trials in Gdansk, Poland across 11 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

PolandOur site in PolandBadaniaKliniczne.pl(opens in a new tab)
Gdansk at a glance
865
clinical trials
  • Research sites11
Type of trial
Recruitment status
Quick filters

865 trials in Gdansk

Open in trial search

Long‑Term Safety and Tolerability of Oral Fesoterodine in Adults with Hallucinations and Delusions Due to Alzheimer’s Disease Psychosis

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:5-[(1R,5R)-3-AZABICYCLO[3.1.0]HEXAN-1-YL]-3-METHYL-1,2,4-OXADIAZOLE
  • Sponsor:Maplight Therapeutics Inc.

Cemsidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Sponsor:C4 Therapeutics Inc.

Remibrutinib in Chronic Spontaneous Urticaria for Patients Who Benefited from a Previous Remibrutinib Trial

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Remibrutinib
  • Sponsor:Novartis Pharma AG

AMG 732 in Patients With Thyroid Eye Disease Who Did Not Respond or Relapsed After Previous Treatment

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:AMG 732
  • Sponsor:Amgen Inc.

Duchenne Muscular Dystrophy in Patients with Gene Mutations Amenable to Exon 44 Skipping Treated with Delpacibart Zotadirsen

Investigational
Countries:PolandPoland
  • Participants:0–17 years
  • Sponsor:Avidity Biosciences Inc.

Asciminib in Pediatric Patients With Philadelphia Positive Chronic Myeloid Leukemia in Chronic Phase

Registered drugNo placebo
Countries:PolandPoland
  • Participants:0–17 years
  • Substances:Asciminib Hydrochloride
  • Sponsor:Novartis Pharma AG

Study of Tirabrutinib, Rituximab, and Temozolomide in Patients with Relapsed/Refractory Primary Central Nervous System Lymphoma

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Rituximab
  • Sponsor:Deciphera Pharmaceuticals Inc.

Obrixtamig, Carboplatin, and Etoposide for First-Line Treatment of Advanced Extrapulmonary Neuroendocrine Carcinoma in DLL3-Positive Patients

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Boehringer Ingelheim Espana S.A.

A Study of BI 764532, Atezolizumab, Carboplatin, and Etoposide in Patients With Extensive-Stage Small Cell Lung Cancer

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Boehringer Ingelheim Espana S.A.

Phase 3 Study of LY4170156 (Sofetabart Mipitecan) with drug combination in platinum‑resistant and platinum‑sensitive ovarian cancer patients

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Eli Lilly & Co.

AZD0120 versus standard regimens in patients with relapsed or refractory multiple myeloma

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:AZD0120
  • Sponsor:AstraZeneca AB

Other cities in Poland

The busiest research cities in the country

All 239 cities in Poland

Clinical research in Gdansk

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on bladder cancer, lymphoma, and various advanced solid tumors. Studies are evaluating novel combination therapies and investigating treatments for non-small cell lung cancer.

  • Bladder Cancer Immunotherapy
  • B-Cell Lymphoma Treatment
  • Gastric Cancer Therapeutics

Research includes promising approaches combining established treatments with new immunotherapy agents.

02 Dermatology Studies

Clinical investigations targeting plaque psoriasis, genital psoriasis, and atopic dermatitis. Studies are examining oral and subcutaneous treatments for moderate to severe skin conditions.

  • Psoriasis Management
  • Hidradenitis Suppurativa
  • Novel Dermatological Therapies

Focus on developing targeted treatments for chronic skin conditions affecting quality of life.

03 Metabolic Disorders

Comprehensive research into obesity and weight management, including studies for patients with and without type 2 diabetes. Trials are evaluating new therapeutic approaches for weight reduction.

  • Weight Management Solutions
  • Diabetes Treatment
  • Cardiovascular Risk Management

Investigation of innovative treatments combining lifestyle modifications with pharmaceutical interventions.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.